Hober Andreas, Henricsson Marcus, Ruckh Tim, Davidsson Pia, Challis Benjamin, Miliotis Tasso
Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden.
R&D Digital Health, AstraZeneca, 431 83 Gothenburg, Sweden.
Anal Chem. 2025 Jul 1;97(25):12953-12962. doi: 10.1021/acs.analchem.4c05455. Epub 2025 Jun 18.
Technological advancements have significantly enhanced proteomics by improving the quality, depth, and timeliness of proteomic data, making mass spectrometry a promising tool for personalized medicine. To enable successful longitudinal population-level monitoring, it is essential to have cost-efficient and convenient sample collection methods that yield reliable results. Microsampling performed by patients in their own homes fulfills this requirement. In this study, we evaluate a novel microsampling device that readily prepares a dried plasma sample from blood collected through a finger prick. The device was assessed quantitatively through a targeted proteomics approach, using a selection of stable isotope-labeled protein fragments as standards for plasma proteins spanning a range from 1300 μM to 30 nM. All samples were analyzed using selected reaction monitoring to ensure quantitative robustness. The device was assessed both from a storage perspective and across a group of healthy donors to ensure reliable performance between individuals. The dried plasma obtained from the device shows an excellent quantitative correlation with conventional plasma ( > 0.99) and high quantitative precision, with a coefficient of variance (CV) below 10% for 80% of all peptides quantified in the group of healthy donors. All of the targets that perform well in the microsampling device also show good long-term stability when stored at room temperature for up to 232 days, further showcasing the potential benefits of collecting samples in a dry format.
技术进步通过提高蛋白质组学数据的质量、深度和及时性,显著增强了蛋白质组学,使质谱分析成为个性化医疗的一种有前景的工具。为了实现成功的纵向人群水平监测,拥有经济高效且便捷的样本采集方法以产生可靠结果至关重要。患者在自己家中进行的微量采样满足了这一要求。在本研究中,我们评估了一种新型微量采样装置,该装置可轻松从通过手指针刺采集的血液中制备干血浆样本。通过靶向蛋白质组学方法对该装置进行了定量评估,使用了一系列稳定同位素标记的蛋白质片段作为血浆蛋白的标准品,其浓度范围从1300 μM到30 nM。所有样本均使用选择反应监测进行分析,以确保定量的稳健性。从储存角度以及在一组健康供体中对该装置进行了评估,以确保个体间的可靠性能。从该装置获得的干血浆与传统血浆显示出极好的定量相关性(> 0.99)和高定量精度,在健康供体组中80%的所有定量肽的变异系数(CV)低于10%。在微量采样装置中表现良好的所有靶标在室温下储存长达232天时也显示出良好的长期稳定性,进一步展示了以干燥形式采集样本的潜在益处。
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2021-4-19
Health Technol Assess. 2006-9
Cochrane Database Syst Rev. 2022-5-20
Cochrane Database Syst Rev. 2022-10-4
J Proteome Res. 2024-8-2
Clin Pharmacol Ther. 2024-1
Health Sci Rep. 2023-8-6
ACS Meas Sci Au. 2022-10-19
Clin Pharmacol Ther. 2022-8
J Mass Spectrom. 2021-4